Friedrich Bayer didn’t start with aspirin. He started with dyes. In 1863, he joined forces with Johann Friedrich Weskott to form Friedr. Bayer et comp. in Barmen, now Wuppertal. Weskott owned a dye company. Bayer was a chemical salesman. They made synthetic colors.
It was a solid start. But it wasn’t yet a household name.
That changed in 1899. Felix Hoffmann, a chemist at the company, stumbled upon a synthesis that tamed salicylic acid. The result was aspirin. It became the brand’s first global hit. The name came from the first syllable of the chemical (acetyl) and the plant source, spirea (the -in).
Bayer incorporated as Farbenfabriken vormals Friedr. Bayer & Co. in 1881. They were serious about research. By the early 1900s, they had subsidiaries in Europe and the US. Exports drove much of their revenue. They built a massive industrial site in Leverkusen. This became their headquarters in 1912.
Today, Bayer AG is a German chemical and pharmaceutical company with a different focus.
The Modern Scope of Bayer
The company has evolved far beyond its dye-making roots. It is now a global player in three main sectors:
- Pharmaceuticals
- Consumer Health
- Crop Science
Headquartered in Leverkusen, near Cologne, the company is a major employer. It has about 90,000 workers worldwide as of 2025. They operate in more than 80 countries.
The shift from dyes to drugs wasn’t immediate. It took decades of expansion. The pharmaceutical division grew alongside the research labs. International presence followed. Now, the company balances its legacy brand with complex modern challenges.
Aspirin remains the most famous invention. But it was just the beginning. The company later expanded into crop science. This diversification shaped its current structure.
Why does this history matter? Because Bayer’s current business models are built on that early foundation of chemical innovation. They still rely on research. They still rely on global distribution.
The name is familiar. The scope is vast. The history is long.
The rise of Bayer’s industrial footprint
Bayer didn’t start as a global titan. It started in Leverkusen. The industrial site there took shape over the late 19th and early 20th centuries. It grew from a factory floor into the company’s headquarters. But the real consolidation of power happened later.
The IG Farben era and post-war split
Carl Duisberg changed the trajectory. The chemist became Bayer’s general director in 1912. He didn’t just manage. He led the push to merge Germany’s chemical giants. That movement culminated in 1925. IG Farben was born. Duisberg served as its first chairman. Bayer stayed inside that cartel structure for two decades. Then came World War II. The Allied authorities dissolved IG Farben in 1945.
Rebuilding from the ashes
By 1951, Bayer was back in business. It emerged as Farbenfabriken Bayer Aktiengesellschaft. The name shifted to the simpler Bayer Aktiengesellschaft in 1972. The company spent the next few decades diversifying. A major move occurred between 1981 and 1999. Bayer held a controlling interest in Agfa-Gevaert. This German-Belgian entity produced photographic film, magnetic tape, and photocopying machines. It was a pivot away from pure chemicals toward consumer and office technology.
Big bets: Schering and Monsanto
The 2000s brought aggressive expansion. In 2002, Bayer established a crop science division. Two years later, in 2006, it acquired Schering AG. Schering was a German pharmaceutical firm. It was notably the largest maker of birth control pills at the time. But the biggest move was waiting in the wings.
In 2016, Bayer agreed to buy Monsanto. The deal valued the American agricultural producer at $63 billion. Monsanto grew crops and made Roundup. That herbicide used glyphosate. The acquisition closed in 2018.
The cost of acquisition
The legal troubles started immediately. A California jury found Monsanto liable in lawsuits claiming Roundup caused cancer. Specifically, non-Hodgkin lymphoma. The liability hit Bayer’s market value hard. Investors got nervous. In 2020, Bayer paid more than $10 billion to settle thousands of claims.
That wasn’t the end. Tens of thousands of lawsuits continued into the 2020s. Bayer set aside billions for settlements and legal costs. In 2025, a U.S. jury awarded $2.1 billion in damages in a single case. It remains one of the largest verdicts to date. The restructuring continues. The financial impact of the Monsanto deal is still unfolding.
The Preemption Victory and Its Limits
The legal battle over Roundup didn’t end with a compromise. It ended with a definitive ruling that reshaped liability for corporate giants. Bayer argued that the U.S. Environmental Protection Agency’s stance on labeling should override state-level concerns. Their logic was simple but potent: if the federal government doesn’t mandate a cancer warning on the bottle, states shouldn’t be allowed to sue over the absence of one.
The Supreme Court agreed.
In a 7–2 decision in 2026, the justices ruled that federal pesticide law preempts state lawsuits regarding missing cancer warnings. This wasn’t a minor procedural dismissal. It was a structural barrier. The ruling was expected to block thousands of pending cases instantly. For plaintiffs’ attorneys, it was a massive setback.
But the victory wasn’t absolute. The Court left the door open for product-design lawsuits. These claims don’t target the label. They target the chemical itself. Did the design of the product make it unreasonably dangerous? That question remains viable. The distinction is subtle but legally profound. One challenges the instruction manual. The other challenges the object in your hand.
A Legacy of Firsts
Beyond the courtroom, Bayer’s history is a catalog of industrial firsts. The brand is defined by the Bayer cross. It is internationally recognized. Almost everyone knows the symbol, even if they don’t trace it back to the chemical works in Elberfeld.
The company didn’t just participate in the chemical revolution. It often started it.
Consider the timeline. In 1898, Bayer mass-produced heroin. It wasn’t a mistake. It was marketed for pain and cough medications. Two years later, in 1899, they introduced aspirin. It became the originator and first marketer of the drug. The brand name came from the chemical components: acetyl (from acetic acid) and -in (the suffix for alkaloids).
This pattern continued. Bayer introduced the first sulfa drug, Prontosil, in 1935. It was an early antibiotic. It changed how doctors treated bacterial infections. Then came polyurethane in 1937. This wasn’t just one product. It was a base material. It became essential for synthetic foams, paints, adhesives, and fibers.
The list is long. Synthetic rubbers. Plastics. Fibers. Insecticides. Dyes. Acetates. Bayer developed scores of these chemicals first. They were the originators. They were the first to bring them to market. This isn’t just nostalgia. It’s a record of R&D dominance that still influences their current portfolio.
The Modern Context
Today, the company faces a different kind of pressure. It’s not just about developing new drugs. It’s about defending old ones. The Roundup ruling provided a shield. But shields can crack. The preemption argument worked for labeling. It might not work for design. It might not work for marketing claims that stretch beyond the label.
The financial impact of the 2026 ruling was immediate. Thousands of cases vanished from the docket. But the uncertainty remains. Which claims survive? Which ones get dismissed? The answer depends on how judges interpret the scope of federal preemption in future suits.
Bayer’s history shows they are willing to push boundaries. They produced heroin before
